domingo, 4 de febrero de 2018

Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics. - PubMed - NCBI

Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics. - PubMed - NCBI



 2018 Jan 27. doi: 10.1007/s00428-017-2288-7. [Epub ahead of print]

Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics.

Hirsch B1,2Endris V3,4Lassmann S3,5Weichert W3,6Pfarr N3,6Schirmacher P3,4Kovaleva V3,5Werner M3,5Bonzheim I3,7Fend F3,7Sperveslage J3,7Kaulich K3,8Zacher A3,8Reifenberger G3,8Köhrer K3,8Stepanow S3,8Lerke S3,9Mayr T3,9Aust DE3,9Baretton G3,9Weidner S3,10Jung A3,10Kirchner T3,10Hansmann ML3,11Burbat L12,3von der Wall E12,3Dietel M12,3Hummel M12,3.

Abstract

The simultaneous detection of multiple somatic mutations in the context of molecular diagnostics of cancer is frequently performed by means of amplicon-based targeted next-generation sequencing (NGS). However, only few studies are available comparing multicenter testing of different NGS platforms and gene panels. Therefore, seven partner sites of the German Cancer Consortium (DKTK) performed a multicenter interlaboratory trial for targeted NGS using the same formalin-fixed, paraffin-embedded (FFPE) specimen of molecularly pre-characterized tumors (n = 15; each n = 5 cases of Breast, Lung, and Colon carcinoma) and a colorectal cancer cell line DNA dilution series. Detailed information regarding pre-characterized mutations was not disclosed to the partners. Commercially available and custom-designed cancer gene panels were used for library preparation and subsequent sequencing on several devices of two NGS different platforms. For every case, centrally extracted DNA and FFPE tissue sections for local processing were delivered to each partner site to be sequenced with the commercial gene panel and local bioinformatics. For cancer-specific panel-based sequencing, only centrally extracted DNA was analyzed at seven sequencing sites. Subsequently, local data were compiled and bioinformatics was performed centrally. We were able to demonstrate that all pre-characterized mutations were re-identified correctly, irrespective of NGS platform or gene panel used. However, locally processed FFPE tissue sections disclosed that the DNA extraction method can affect the detection of mutations with a trend in favor of magnetic bead-based DNA extraction methods. In conclusion, targeted NGS is a very robust method for simultaneous detection of various mutations in FFPE tissue specimens if certain pre-analytical conditions are carefully considered.

KEYWORDS:

Amplicon-based next-generation sequencing; FFPE cancer samples; German Cancer Research Centers (DKTK-sites); MiSeq™; Multicenter trial; PGM™

PMID:
 
29374318
 
DOI:
 
10.1007/s00428-017-2288-7

No hay comentarios:

Publicar un comentario